Beyond Air Secures Up to \$30.1 Million in Private Placement to Fund Next-Gen LungFit PH Launch
Beyond Air, Inc. (NASDAQ: XAIR), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) for patient care, has announced a significant private placement financing of up to \$30.1 million. This development is poised to have a substantial impact on the company’s operations, potential product launches, and could influence its share price.
Key Highlights of the Private Placement
- Size and Structure: The offering consists of up to \$30.1 million in gross proceeds, before fees and expenses, assuming full exercise of all attached warrants for cash.
- Immediate and Potential Proceeds: The company will receive \$10.2 million upfront, with an additional \$10.0 million potentially available from short-term Series A warrants (accelerated upon FDA clearance) and another \$10.0 million from longer-term Series B warrants.
- Pricing: Shares and accompanying warrants are being sold at \$5.66 per share to institutional investors and \$5.76 per share to certain directors and officers. For some investors, pre-funded warrants substitute for common stock at \$5.65 per share, accounting for a \$0.0001 exercise price.
- Participants: The financing is led by institutional healthcare investors, with additional participation from company leadership, including CEO Robert Goodman and CFO Dan Moorhead.
- Warrants:
- Series A Warrants: Up to 1,805,846 shares at \$5.51 per share, expiring on the earlier of one year from issuance or 45 days after FDA approval of LungFit II (subject to registration statement effectiveness).
- Series B Warrants: Up to 1,805,846 shares at \$5.51 per share, expiring five years from issuance.
- Use of Proceeds: Funds will be used primarily for working capital and to support the planned commercial launch of the second-generation LungFit PH, pending regulatory approval.
- Closing and Conditions: The transaction is expected to close on or around July 31, 2026, subject to customary closing conditions.
- Registration Rights: Beyond Air is required to file an initial registration statement with the SEC for the resale of the shares and warrants within 15 days of closing and achieve effectiveness within 75 days post-filing in case of a full review.
Strategic and Shareholder-Relevant Insights
- Product Launch Funding: The capital raised will provide the company with financial flexibility to execute the commercial launch of the next-generation LungFit PH device, a key growth catalyst pending FDA approval.
- FDA Approval and Warrants Acceleration: The Series A warrants are structured to accelerate upon FDA clearance, which could lead to additional near-term funding. However, the timing and likelihood of FDA approval remain uncertain and are risk factors for shareholders.
- Insider Participation: Participation by senior management and directors signals confidence in the company’s prospects and aligns their interests with shareholders.
- Potential Dilution: Full exercise of all warrants would increase the number of shares outstanding, potentially diluting existing shareholders’ holdings.
- Regulatory Risks: The success of the offering and warrant exercise is tied to FDA approval and registration statement effectiveness. Delays or adverse decisions could impact both funding and share price.
LungFit PH and Beyond Air’s Pipeline
Beyond Air’s LungFit PH is a novel, cylinder-free nitric oxide delivery system designed to generate NO from ambient air on demand. The system is already FDA approved and CE marked for treating hypoxic respiratory failure in term and near-term neonates. The next-generation device, LungFit PH II, is pending regulatory approval and is intended to further expand the company’s market reach. The LungFit platform also targets severe and chronic lung infections, with investigational versions in development for home use.
Forward-Looking Statements and Risks
Investors should note that the company’s plans are subject to significant risks, including completion of the offering, FDA review and approval timelines, the ability to raise additional capital, successful registration of resale shares, and other regulatory and development uncertainties. The company’s forward-looking statements reflect current views but are subject to change based on multiple factors, as detailed in their filings.
Placement Agents
Cantor is leading the placement, with Citizens Capital Markets and Lake Street serving as additional placement agents.
Important Notice to Investors
The securities are being offered in a private placement under exemptions to SEC registration requirements and are not immediately available for public trading unless registered or exempt.
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any securities. All statements regarding future events are subject to risks and uncertainties, and actual results may differ materially. Investors should consult the company’s SEC filings and their own financial advisors before making investment decisions.
